Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GLAUKOS CORPORATION

(GKOS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
48.2(c) 49.16(c) 49.45(c) 51(c) 51.01(c) Last
738 143 756 398 799 336 605 827 401 860 Volume
+0.46% +1.99% +0.59% +3.13% +0.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 295 M - -
Net income 2021 -60,6 M - -
Net cash position 2021 129 M - -
P/E ratio 2021 -35,0x
Yield 2021 -
Sales 2022 319 M - -
Net income 2022 -67,1 M - -
Net cash position 2022 113 M - -
P/E ratio 2022 -34,7x
Yield 2022 -
Capitalization 2 359 M 2 359 M -
EV / Sales 2021 7,56x
EV / Sales 2022 7,05x
Nbr of Employees 653
Free-Float 96,7%
More Financials
Company
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the... 
More about the company
Ratings of Glaukos Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about GLAUKOS CORPORATION
07/30GLAUKOS : Berenberg Bank Adjusts Glaukos' Price Target to $68 From $90, Maintain..
MT
07/28GLAUKOS : Citigroup Adjusts Glaukos' Price Target to $52 From $94, Maintains Neu..
MT
07/27NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
07/26GLAUKOS : Stephens Downgrades Glaukos to Equal-Weight From Overweight; Price Tar..
MT
07/22GLAUKOS : Technologies Featured in Numerous Scientific Abstracts at the 2021 Ame..
BU
07/21NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
07/20Today on Wall Street: Investors spooked by stunning rise in infections
07/20GLAUKOS CORP : Regulation FD Disclosure (form 8-K)
AQ
07/20ANALYST RECOMMENDATIONS : Deliveroo, IBM, Intercontinental Hotels, LivaNova, Via..
07/20GLAUKOS : Wells Fargo Downgrades Glaukos to Underweight From Equal-Weight; Price..
MT
07/16GLAUKOS : Berenberg Bank Adjusts Glaukos PT to $90 From $103, Maintains Buy Rati..
MT
07/15GLAUKOS CORPORATION : to Release Second Quarter 2021 Financial Results after Mar..
BU
07/15Today on Wall Street: The Fed stands its ground
07/15ANALYST RECOMMENDATIONS : Crowdstrike, Fortinet, Hiscox, L Brands, Nasdaq 100.....
07/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
More news
News in other languages on GLAUKOS CORPORATION
2017Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | GKOS | US3773221029 | MarketScreener
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 51,01 $
Average target price 68,80 $
Spread / Average Target 34,9%
EPS Revisions
Managers and Directors
Thomas William Burns President, Chief Executive Officer & Director
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
William J. Link Chairman
L. Jay Katz Chief Medical Officer
Tomas Navratil Senior Vice President-Research & Development
Sector and Competitors